Several rival companies set to launch antiviral pills for COVID-19
With Merck and Pfizer preparing to release clinical trial results from its experimental COVID-19 antiviral pills, rivals are lining up with what they hope will prove to be more potent and convenient oral treatments of their own.
Enanta Pharmaceuticals, Pardes Biosciences, Japan’s Shionogi, and Novartis have all designed their own antiviral pills against coronavirus, with the hopes that their treatments can outstrip rivals.
Several rival companies set to launch antiviral pills for COVID-19 | Pharmafile
![[branded content] De vijf belangrijkste customer experience trends voor 2024](https://www.pharmamarketeer.nl/wp-content/uploads/2024/04/customer-experience-80x60.jpg)
